Arrowhead Pharmaceuticals
ARWR · NASDAQ
Bulios Fair Price
$50.64
21.1% downside
Current Price
$64.19
According to Bulios Fair Price, ARWR is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Arrowhead Pharmaceuticals is a U.S.-based biotechnology company focused on developing innovative therapies targeting genetic diseases. The company is particularly known for its advanced RNA interference (RNAi) technology, which enables the "turning off" or regulation of genes associated with various diseases. Arrowhead Pharmaceuticals focuses on developing drugs for the treatment of rare and chronic conditions, including genetic disorders, viral infections, and cardiovascular diseases, aiming to improve treatment outcomes and the quality of life for patients.
Sector
Healthcare
Industry
Biotechnology
CEO
Christopher R. Anzalone
Employees
711
Headquarters
Pasadena
Upcoming events
Earnings
Upcoming earnings report